Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenytoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.96 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.96 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.96 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.96 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.96 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.96 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenytoin SCHEMBL5499612 | 0.98 | CYP2C9 (1.00) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL3440 | 0.98 | CYP2C9 (1.00) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL29521348 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL157671 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL28548871 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL5160618 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL1461588 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL2905857 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL10406406 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A | |
| Phenytoin SCHEMBL2140317 | 0.96 | CYP2C9 (0.96) | CYP2C9CACNA1FALDH1A1MAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030056896-A1 | Effective therapy for epilepsies | JAO FRANK (US) | 2003-03-27 | — | — | US | claimed |
| EP-0758228-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| CN-112741811-A | Novel continuous controllable drug delivery system for central nervous system drugs | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20040191314-A1 | Antiepileptic dosage form and process for protecting antiepileptic drug | JAO FRANK | 2004-09-30 | — | — | US | disclosed |
| US-20030056896-A1 | Effective therapy for epilepsies | JAO FRANK (US) | 2003-03-27 | — | — | US | disclosed |
| US-5955103-A | Dosage form comprising antiepileptic drug | ALZA CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5906832-A | Method for treating epilepsies | ALZA CORPORATION (US) | 1999-05-25 | — | — | US | disclosed |
| US-5876750-A | Effective therapy for epilepsies | ALZA CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5863558-A | Effective therapy for epilepsies | ALZA CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5660861-A | Effective therapy for epilepsies | ALZA CORPORATION (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0758228-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |